Investors
0 investorsAll
Early stage
Mid stage
Late stage
No investors in this category
Born from a collaboration between leading expertise in computational biology (genomic sequence analysis) and advanced immune validation technologies developed at the Institut Curie, Cereus delivers what current immunotherapies cannot: a scalable, off-the-shelf vaccine built on truly tumor-specific antigens discovered in the dark genome
0
Total investors
0
Early stage
0
Mid stage
0
Late stage
—
Founded
Find investors for your startup like CEREUS BIOSCIENCES
Gritt sends AI-personalised outreach to each investor — from your Gmail